DDInter396 DDInter233
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nifedipine
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nitrendipine
Nitrendipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nisoldipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} (Compound) resembles {v} (Compound) Amlodipine
Amlodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Felodipine
Felodipine {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine {u} (Compound) resembles {v} (Compound) Nimodipine
Nimodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) resembles Nifedipine (Compound) and Nifedipine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Clevidipine (Compound) resembles Nitrendipine (Compound) and Nitrendipine (Compound) resembles Nisoldipine (Compound) and Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) resembles Felodipine (Compound) and Felodipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clevidipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib